Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced equity inducement grants for 27 new non-executive employees. The compensation package includes 75,850 non-qualified stock options with an exercise price of $26.85 per share and 53,400 restricted stock units (RSUs).
The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest in equal annual installments over four years. These grants were made under the company's 2021 Employment Inducement Incentive Award Plan, complying with Nasdaq Listing Rule 5635(c)(4).
Crinetics Pharmaceuticals (Nasdaq: CRNX) ha annunciato assegnazioni di incentivi azionari per 27 nuovi dipendenti non dirigenti. Il pacchetto retributivo comprende 75,850 opzioni su azioni non qualificate con prezzo di esercizio di $26.85 per azione e 53,400 unità azionarie vincolate (RSU).
Le opzioni matureranno in quattro anni, con il 25% che si matura dopo il primo anno e il resto che si matura mensilmente nei successivi 36 mesi. Le RSU si matureranno in quote annuali uguali per quattro anni. Queste assegnazioni sono state effettuate ai sensi del piano aziendale 2021 Employment Inducement Incentive Award Plan, in conformità con la Regola di quotazione Nasdaq 5635(c)(4).
Crinetics Pharmaceuticals (Nasdaq: CRNX) anunció concesiones de incentivos en acciones para 27 nuevos empleados no ejecutivos. El paquete de compensación incluye 75,850 opciones sobre acciones no calificadas con un precio de ejercicio de $26.85 por acción y 53,400 unidades restringidas de acciones (RSU).
Las opciones se consolidarán a lo largo de cuatro años, con el 25% consolidado tras el primer año y el resto consolidándose mensualmente durante 36 meses. Las RSU se consolidarán en cuotas anuales iguales durante cuatro años. Estas concesiones se realizaron en el marco del 2021 Employment Inducement Incentive Award Plan de la compañía, cumpliendo con la Norma de cotización Nasdaq 5635(c)(4).
Crinetics Pharmaceuticals (Nasdaq: CRNX)는 27명의 신규 비임원 직원에게 주식 인센티브 부여를 발표했습니다. 보상 패키지에는 행사가 $26.85인 75,850개의 비자격 주식매수선택권과 53,400개의 제한주식단위(RSU)가 포함됩니다.
주식매수선택권은 4년 동안 베스팅되며, 1년 후 25%가 베스트되고 나머지는 이후 36개월에 걸쳐 매월 베스팅됩니다. RSU는 4년 동안 매년 동일한 비율로 베스팅됩니다. 이 부여는 회사의 2021 Employment Inducement Incentive Award Plan에 따라 이루어졌으며 Nasdaq 상장 규칙 5635(c)(4)를 준수합니다.
Crinetics Pharmaceuticals (Nasdaq: CRNX) a annoncé des attributions d'incitation en actions pour 27 nouveaux employés non dirigeants. Le package de rémunération comprend 75,850 options d'achat d'actions non qualifiées à un prix d'exercice de $26.85 par action et 53,400 unités d'actions restreintes (RSU).
Les options seront acquises sur quatre ans, avec 25 % acquis après un an et le reste acquis mensuellement sur 36 mois. Les RSU seront acquises en versements annuels égaux sur quatre ans. Ces attributions ont été effectuées dans le cadre du 2021 Employment Inducement Incentive Award Plan de la société, conformément à la règle de cotation Nasdaq 5635(c)(4).
Crinetics Pharmaceuticals (Nasdaq: CRNX) hat Aktienanreiz-Zuweisungen für 27 neue nicht-exekutive Mitarbeiter angekündigt. Das Vergütungspaket umfasst 75,850 nicht qualifizierte Optionen mit einem Ausübungspreis von $26.85 pro Aktie und 53,400 Restricted Stock Units (RSUs).
Die Optionen werden über vier Jahre vesten, wobei 25% nach einem Jahr vesten und der Rest monatlich über 36 Monate. Die RSUs vesten in gleichen jährlichen Raten über vier Jahre. Diese Zuweisungen erfolgten im Rahmen des 2021 Employment Inducement Incentive Award Plan des Unternehmens und entsprechen der Nasdaq-Listing-Regel 5635(c)(4).
- None.
- None.
SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 75,850 shares of its common stock and granted an aggregate of 53,400 restricted stock unit (“RSU”) awards to 27 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2021 Inducement Plan is used exclusively for granting equity awards to individuals who were not previously employees of Crinetics, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Crinetics, pursuant to Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 450-6464
FAQ
What equity grants did Crinetics Pharmaceuticals (CRNX) announce in August 2025?
What is the vesting schedule for CRNX's August 2025 stock option grants?
What is the exercise price for Crinetics' August 2025 stock options?
How do the RSUs vest in Crinetics' August 2025 inducement grants?
